Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Smoking Cessation Prior to Gynecological Surgery

8 de mayo de 2019 actualizado por: Katja Stenström Bohlin, Sahlgrenska University Hospital, Sweden

Smoking Cessation Prior to Gynecological Surgery - a Registry-based Randomized Trial

This study evaluates whether current smokers scheduled for gynecological surgery will stop smoking to a higher extent if they or the surgeon is exposed to information on smoking cessation prior to surgery in a web-based questionnaire in the Swedish National quality register for gynecological surgery, GynOp.

Descripción general del estudio

Estado

Terminado

Descripción detallada

Peri-operative smoking cessation should be introduced 4-6 weeks before surgery and continued 4-6 weeks after surgery to decrease postoperative complications. The purpose of the study is to increase the exposure to smoking cessation information pior to surgery using a web-based quality register. The hypothesis is that this will lead to an increase in perioperative smoking cessation.

Women scheduled for gynecological surgery who report current smoking will be enrolled in the study. They will be randomly assigned to different sources of information about smoking cessation before surgery. The web-based Swedish national quality register for gynecological surgery, GynOp, will be utilized for randomization, obtaining information about the participant and the surgery performed as well as for follow-up.

GynOp The register was established in 1997 and 90% of gynecological surgical clinics in Sweden contribute information. The conversion from paper forms to on-line registration started in 2008. When scheduled for surgery a health declaration and a questionnaire about symptoms is sent to the patients primarily via their e-mail address for direct on-line registration. This is used in 41% of the cases and the response rate has been reported to be 83%. If an e-mail address is missing, or if preferred by the patient, information is obtained by postal questionnaires (today used in 59% with a response rate of 87%). It has been previously reported that there were no differences in patient characteristics between these two means of contact except that patients without an e-mail address were slightly older and answered more frequently than patients with e-mail. The advantage of the web-based version is not only that the health declaration is sent directly to the clinic and automatically included in the medical record, but relevant information to the patient can be added in the health declaration. The on-line web-version can also be used in a randomization process, which we will utilize in this study.

Data in the register is collected prospectively from patient questionnaires and doctors' forms. The patient receives written information about the register and has the opportunity to decline participation. Pre-operatively, the patient fills in a questionnaire including a health declaration with questions on comorbidity, medication and smoking status. The surgeon registers data on preoperative findings and surgical history at the enrollment before surgery. Peroperative data and events before discharge are also registered in two different forms by the surgeon. Eight weeks postoperatively the patient receives a questionnaire with questions concerning the results of the surgery and any complaints or complications. The forms are evaluated by the surgeon and data registered if there have been any complications.

The randomisation process

When smoking is reported by the participant in the web-based health declaration, she is automatically randomized to one of four alternatives. The allocation ratio of randomization will be 1:4 between the 4 arms:

Group 1 serves as a control group and receives no specific information about smoking cessation Group 2 the participant receives directly the following written recommendation in the web-based health declaration "You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended" Group 3 The smoking status of the patient is alerted to the surgeon when filling in the preoperative form with the text " the patient smokes, recommend smoking cessation" Group 4, is a combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the patient is a smoker and instructed to recommend smoking cessation as in group 3.

In the postoperative questionnaire two months after surgery the participant is asked to participate in a research study including questions about smoking cessation and an informed consent form will be presented and completed. Hence, she will thereby be blinded to the study when she receives the smoking cessation information in the preoperative questionnaire. The intention for this procedure is to avoid introducing any bias of being included in a study and to be able to study the effect of a recommendation in the register in a real world setting. This was accepted by the Ethics Committee and to be exposed to smoking cessation information was not considered an ethical problem as patients are routinely given written information on smoking cessation by the clinics even outside the study. The patient has the opportunity to decline participation two months after surgery when the additional questionnaire on smoking cessation is presented.

Five questions on smoking cessation will be added to the ordinary postoperative questionnaire. The questions includes whether or not the woman has received smoking cessation information, from whom she has been given the information and the duration of smoking cessation in connection to surgery. These questions has gone through several phases of validation prior to study start. The randomization process in the register has also been tested thoroughly since this is the first time a randomized study is carried out in this register.

Tipo de estudio

Intervencionista

Inscripción (Actual)

1609

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Gothenburg, Suecia, 41345
        • Department of Obstetrics and gynecology

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Planned gynecological surgery and invited to participate in GynOp
  • Current smokers
  • Ability to fill in a web-version of a questionnaire in Swedish

Exclusion Criteria:

  • Non-smokers
  • Surgery was not performed
  • No response to follow-up questionnaire

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Control group
No information on smoking cessation
Comparador activo: Written information, GynOp
When reporting being a current smoker in the health declaration on-line the participant receives the following written recommendation in the web-based health declaration "You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended"
Smoking cessation is recommended 6 weeks before and after surgery
Comparador activo: Doctor informed
The smoking status of the participant is alerted to the surgeon when filling in the preoperative form with the text " the patient smokes, recommend smoking cessation"
Smoking cessation is recommended 6 weeks before and after surgery
Comparador activo: Written information, GynOp + doctor informed
A combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the participant is a smoker and instructed to recommend smoking cessation as in group 3.
Smoking cessation is recommended 6 weeks before and after surgery

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Smoking cessation
Periodo de tiempo: At two months after surgery
Change in smoking habits measured by a questionnaire two months after surgery. The participants were asked to report their smoking habits at 6 weeks, 3-6 weeks and 1-3 weeks before surgery, the week of surgery and 1-3 weeks and 3-6 weeks after surgery. The answering alternatives were "did not smoke", "smoked less than ususal" or "smoked as usual". The rate of nonsmoking will be measured at the different time span before and after surgery.
At two months after surgery

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Postoperative complications
Periodo de tiempo: Registered complications within 8 weeks after surgery
The rate of minor and major complications, including infections after surgery
Registered complications within 8 weeks after surgery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Katja S Bohlin, MD, Department of Obstetrics and Gynecology Sahlgrenska University Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de noviembre de 2015

Finalización primaria (Actual)

6 de diciembre de 2017

Finalización del estudio (Actual)

6 de diciembre de 2017

Fechas de registro del estudio

Enviado por primera vez

5 de mayo de 2019

Primero enviado que cumplió con los criterios de control de calidad

6 de mayo de 2019

Publicado por primera vez (Actual)

8 de mayo de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de mayo de 2019

Última actualización enviada que cumplió con los criterios de control de calidad

8 de mayo de 2019

Última verificación

1 de mayo de 2019

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • Q4-15-035 E4

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

The study is completed and data will be described in a scientific publication within six months

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir